• Ongoing phase 3 study with up to 495 patients
  • Including RRMM patients who are refractory to lenalidomide
  • Direct comparison with pomalidomide in patients treated with IMiDs and PIs, and who have become refractory to their last line of therapy
  • The study is designed to demonstrate benefit in comparison with pomalidomide
  • To obtain approval in Europe, the only requirement is to demonstrate that melflufen has similar benefit
  • Started in Q2 2017 enrollment ongoing with 450 patients enrolled in May 2020